U.S. pharma big copyright scrapped two experimental weight loss products past year—a after-each day tablet, lotiglipron, because of elevated liver enzymes as well as a twice-each day tablet, danuglipron, resulting from potent Unwanted side effects—but CEO Albert Bourla has explained